Liquidia Co. (NASDAQ:LQDA) Receives $26.63 Average Price Target from Brokerages

Shares of Liquidia Co. (NASDAQ:LQDA) have earned a consensus rating of “Buy” from the nine ratings firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $26.63.

Several research analysts recently commented on LQDA shares. Needham & Company LLC raised their target price on Liquidia from $19.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, March 20th. Scotiabank reiterated an “outperform” rating on shares of Liquidia in a research report on Thursday, March 20th. HC Wainwright reissued a “buy” rating and issued a $29.00 target price on shares of Liquidia in a research note on Thursday, March 20th. Finally, Wells Fargo & Company initiated coverage on shares of Liquidia in a research note on Friday, December 20th. They set an “overweight” rating and a $20.00 price target for the company.

Insider Buying and Selling

In other news, insider Rajeev Saggar sold 2,445 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $13.00, for a total transaction of $31,785.00. Following the sale, the insider now directly owns 267,943 shares of the company’s stock, valued at $3,483,259. This represents a 0.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Russell Schundler sold 16,393 shares of the firm’s stock in a transaction that occurred on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $193,109.54. Following the completion of the sale, the general counsel now directly owns 573,478 shares of the company’s stock, valued at approximately $6,755,570.84. This represents a 2.78 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 71,245 shares of company stock worth $843,326 in the last three months. Insiders own 30.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of LQDA. LM Advisors LLC acquired a new position in shares of Liquidia during the fourth quarter valued at $25,948,000. Whitefort Capital Management LP raised its holdings in Liquidia by 119.8% during the 3rd quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company’s stock worth $17,020,000 after purchasing an additional 927,546 shares during the last quarter. Invesco Ltd. lifted its position in Liquidia by 2,675.0% during the 4th quarter. Invesco Ltd. now owns 700,171 shares of the company’s stock valued at $8,234,000 after purchasing an additional 674,940 shares during the period. Janus Henderson Group PLC boosted its stake in shares of Liquidia by 1,484.5% in the 4th quarter. Janus Henderson Group PLC now owns 535,552 shares of the company’s stock valued at $6,293,000 after purchasing an additional 501,752 shares during the last quarter. Finally, Mirabella Financial Services LLP acquired a new stake in shares of Liquidia during the 4th quarter worth approximately $5,880,000. 64.54% of the stock is currently owned by institutional investors.

Liquidia Stock Performance

NASDAQ:LQDA opened at $15.09 on Thursday. The firm’s 50-day moving average is $15.10 and its 200-day moving average is $12.42. The company has a market cap of $1.29 billion, a price-to-earnings ratio of -9.26 and a beta of 0.07. Liquidia has a 52-week low of $8.26 and a 52-week high of $16.81.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.08). Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. The firm had revenue of $2.92 million during the quarter, compared to analyst estimates of $4.60 million. Equities analysts predict that Liquidia will post -1.51 EPS for the current year.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).